NCT05631223Completed
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA): Implementation of PsOWellTM in PsA
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 101 (actual)
- First submitted
- 18 Nov 2022
- Start date
- 10 Mar 2023
- Primary completion date
- 6 Feb 2026
- Lead sponsor
- University of Pennsylvania
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT05631223
What you commit to
- Study type: Interventional
- Participants enrolled: 101
- From 10 Mar 2023 to the primary completion date, 6 Feb 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to provide informed consent.
- Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks.
- PsAID score ≤4
Who the study is looking for
- Population: Patients with Psoriatic Arthritis
- Age 18-89.
- Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
- Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
- Meet CASPAR criteria.
- Provision of signed and dated informed consent form.
- Willingness to comply with all study procedures and availability for duration of the study.
- Has access to a mobile phone or other mobile device.
Age in the registry: 18 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.